Overexpressed VLA-4 on endothelial cell membrane camouflaging the pathological reactive oxygen species responsive prodrug to enhance target therapy for atherosclerosis

Zhong, Yuan; Qu, Kai; Yan, Wenhua; Zhang, Kun; Xian, Qiming; Wang, Yi; Meng, Yan; Wu, Shuai; Zhu, Li; Obaid, Essam Abdo Mohammed Saad; Wang, Guixue; Wu, Wei

doi:10.1016/j.cej.2022.136198

Cited by 13 publications

(12 citation statements)

References 48 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…OEMs were prepared as previously described. 23 OEMs and ETBNPs were co-cultured for 30 min at 37 °C to harvest OEM-ETBNPs. For OEM-ETBPD synthesis, OEMs and ETBPD were co-extruded using an Avestin mini-extruder (Avestin, LF-1, Canada, 100 nm polycarbonate porous membrane) for 10 times to harvest OEM-ETBPD.…”

Section: Methodsmentioning

confidence: 99%

Universal cell membrane camouflaged nano-prodrugs with right-side-out orientation adapting for positive pathological vascular remodeling in atherosclerosis

Qin,

Zhu,

Zhong

et al. 2024

Chem. Sci.

Self Cite

View full text Add to dashboard Cite

show abstract

Section: Methodsmentioning

confidence: 99%

Universal cell membrane camouflaged nano-prodrugs with right-side-out orientation adapting for positive pathological vascular remodeling in atherosclerosis

Qin,

Zhu,

Zhong

et al. 2024

Chem. Sci.

Self Cite

View full text Add to dashboard Cite

show abstract

“…The membrane of ECs overexpressing VLA‐4 (OEM) was isolated and camouflaged on ROS‐responsive rapamycin NPs (RAP NPs) to obtain biomimetic nanodrugs of OEM@RAP NPs ( Figure 8 ). [ 154 ] The NPs significantly increased accumulation in lesion site, and inhibited the occurrence and development of AS (Figure 8B).…”

Section: Diagnosis and Therapymentioning

confidence: 99%

Recent Advances in Cell‐Based Nanotherapy for Cardiovascular Diseases

Hao

2023

Macromolecular Bioscience

View full text Add to dashboard Cite

Cell‐based nanotherapy holds great potential to transform diagnosis and treatment patterns for human diseases, especially for cardiovascular diseases (CVDs). Surface coating with cell membrane has become a powerful strategy for functionalization of therapeutic nanoparticles to achieve biological performances of superior biocompatibility, immune evasion, and specificity. Additionally, extracellular vesicles (EVs) play key roles in the progression of CVDs with their ability of transferring cargos to distant tissues, thus emerging as an appealing option for the diagnosis and therapy of CVDs. In this review, recent progress in cell‐based nanotherapy for CVDs is summarized, and different sources of EVs and biomimetic nanoplatforms derived from natural cells are highlighted. Meanwhile, their promising biomedical applications in the diagnosis and targeted treatment of different CVDs are also provided, followed by a discussion of their potential challenges and future prospects.

show abstract

“…[240][241][242] For example, Wu and co-workers prepared a membrane-functionalized drug delivery system (OEM@RAP NPs) consisting of endothelial cell membranes overexpressing very late antigen-4 (VLA-4) (OEM) as a shell and ROS-responsive camouflage rapamycin NPs (RAP NPs) as a core to enhance active target drug delivery and ROS-responsive drug release for AS therapy (Figure 17E). [243] VLA-4 is a high affinity ligand of vascular cell adhesion molecule-1 (VCAM-1, a receptor of inflamed cells including macrophages and VSMCs) and the abnormal proliferation of VSMCs contributes to the thickening of the arterial intima, leading to the aggravation of AS. RAP was recognized to pos-sess antiproliferative actions that can be effective in preventing the development of AS.…”

Section: Drug Therapymentioning

confidence: 99%

Nanomaterials Responsive to Endogenous Biomarkers for Cardiovascular Disease Theranostics

Wei

Jiang

et al. 2023

Adv Funct Materials

View full text Add to dashboard Cite

Cardiovascular disease (CVD) is the number one cause of death worldwide, which propels the development of advanced technologies for CVD diagnosis and treatment. Biomarker-responsive nanomaterials are appealing therapeutic platforms that provide new horizons for CVD theranostics. In this review, recent advances in nanomaterials with endogenous biomarkers as stimuli or targets for CVD theranostics is presented. First, the categories of biomarkers involved are comprehensively itemized based on pathological mechanisms including pH, reactive oxygen species, lipids, enzymes, macrophage receptors, subendothelium components, platelet receptors, inflammation, and osteopontin. The role of these biomarkers in bridge-building between nanomaterials and CVD is then presented. Next, the biomedical applications of nanomaterials responsive to endogenous biomarkers as stimuli or targets for the diagnosis and treatment of CVD are elaborated. Finally, the challenges and future research directions of biomarker-responsive nanomaterials in CVD are also discussed. This review will provide scientific guidance to facilitate clinical applications of biomarker-responsive nanomaterials.

show abstract

Overexpressed VLA-4 on endothelial cell membrane camouflaging the pathological reactive oxygen species responsive prodrug to enhance target therapy for atherosclerosis

Cited by 13 publications

References 48 publications

Universal cell membrane camouflaged nano-prodrugs with right-side-out orientation adapting for positive pathological vascular remodeling in atherosclerosis

Universal cell membrane camouflaged nano-prodrugs with right-side-out orientation adapting for positive pathological vascular remodeling in atherosclerosis

Recent Advances in Cell‐Based Nanotherapy for Cardiovascular Diseases

Nanomaterials Responsive to Endogenous Biomarkers for Cardiovascular Disease Theranostics

Contact Info

Product

Resources

About